Back to search

University of Patras

Analysis of the mechanisms of function of T-cell products in cellular immunotherapy

Abstract

dc:description

Allogeneic haematopoietic cell tranplantation (Allo-HCT) has become a standard treatment for patients with marrow failure syndromes and hematologic malignancies such as acute leukaemia. However, this treatment is frequently accompanied by the occurrence of Graft-versus-Host Disease (GvHD), a common life-threatening complication in which donor-derived T cells recognise and attack the host’s normal tissues. This phenomenon can occur either early (aGvHD) or later (cGvHD) following allo-HCT and can transpire even when aggressive immunosuppressive prophylaxis is given or even when the donor is an HLA-matched sibling. Despite ground-breaking discoveries in GvHD pathobiology and advances in our understanding of the underlying mechanisms of this disease, conventional immunosuppressive pharmacotherapy remains the backbone of GvHD prophylaxis and treatment. A promising alternative strategy against GvHD is immunotherapy employing the adoptive transfer of T-cells with regulatory properties (Tregs) as a living drug aiming to avoid prolonged pharmacological immunosuppression while preserving the beneficial Graft-versus-Leukaemia effect. Our approach aspired to mimic the physiological mechanism of the successful immune tolerance transpiring during pregnancy, where HLA-G -a well-known immunoregulatory molecule- is expressed in the placenta thereby guarding the “semi-allogeneic” fetus from maternal immune rejection. Since the HLA-G gene is epigenetically repressed after prenatal life and the methylation status of HLA-G promoter regulates its transcriptional activity, we showed in small-scale in vitro experiments that exposure of human peripheral T cells to hypomethylating agents (Has) induces a de novo and stable expression of HLA-G, in turn, converting them to Tregs with in vitro immunosuppressive functions. Subsequently, we developed and validated the manufacturing process of a HLA-G+ T cell (G+ cell)-enriched product, termed iG-Tregs, using a clinical scale and GMP-grade protocol. iG-Tregs can be consistently and robustly produced and display suppressive properties with a favourable safety profile both in vitro and in vivo. The current thesis plays a pivotal part in the translation journey of iG-Tregs as it focuses on elucidating the molecular aspects of G+ cell biology, the design of an interventional clinical trial to translate iG-Tregs as adoptive cell immunotherapy in the context of GvHD post allo-HCT and finally to provide a framework upon which to gain insight into the biological events occurring following this treatment in the human in vivo setting.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Lysandrou, Memnon
  • Λυσάνδρου, Μέμνων

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/55962

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Lysandrou, Memnon; Λυσάνδρου, Μέμνων. Analysis of the mechanisms of function of T-cell products in cellular immunotherapy. University of Patras, 2024. http://hdl.handle.net/10442/hedi/55962